Generalizability of HFrEF trials 33 SUPPLEMENTARY MATERIAL Supplementary table 1. Characteristics, inclusion and exclusion criteria of trials Study name BEAUTIFUL CONFIRM-HF FAIR-HF PANTHEON SHIFT Phase III IV III II III Drug Ivabradine Ferric carboxymaltose Ferric carboxymaltose Neladenosone bialanate Ivabradine Year 2005-2008 2011 - 2014 2007-2009 2017-2018 2006-2010 Number of patients 10917 304 456 427 6505 Duration of followup 12 months 52 weeks 40 weeks 26 weeks 30 months Inclusion Criteria Male or female patient of any ethnic origin, nondiabetic (type I or II) aged ≥ 55 years, or diabetic (type I or II) aged ≥ 18 years At least 18 years of age. At least 18 years of age and signed written informed consent. Men or women aged 18 years and older Male or female patients aged ≥ 18 years 2.1
RkJQdWJsaXNoZXIy MjY0ODMw